News
Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback